<DOC>
	<DOC>NCT02519816</DOC>
	<brief_summary>Phase II multicenter, Canadian only study - open to 25 subjects. Study open to subjects with steroid-refractory or dependent chronic graft vs host disease. Series of 6 aphereses and 28 re-infusions over 24 weeks. Primary endpoint is FFS at 24 weeks. Primary objective is to measure the efficacy of CARE (Continuous Alloreactive T-Cell depletion and Regulatory T-cell Expansion)</brief_summary>
	<brief_title>Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD</brief_title>
	<detailed_description />
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Plasma-lyte 148</mesh_term>
	<criteria>(Main) 1. Newly diagnosed chronic GVHD as defined by the National Institutes of Health (NIH) Consensus with no more than 24 weeks of treatment with systemic steroids. AND 2. Chronic GVHD must be refractory or dependent to standard therapy, defined as (one of the following): Progression on prednisone 7 mg/kg/week for 2 weeks, or Stable disease on â‰¥ 3.5 mg/kg/week of prednisone for 48 weeks, or Inability to taper prednisone below 3.5 mg/kg/week. (Main) 1. Persistent, recurrent or lateonset acute GVHD, without signs of chronic GVHD. OR 2. Overlap GVHD syndrome with uncontrolled features of previously diagnosed acute GVHD. OR 3. Treatment with more than two systemic nonsteroidal immunosuppressants within 4 weeks prior to enrollment. OR 4. Time from allogeneic transplantation &gt; 2 years. OR 5. Lymphocyte count &lt; 0.2 x 109/L on two last consecutive CBCs before inclusion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>post stem cell transplantation</keyword>
	<keyword>Steroid refractory</keyword>
	<keyword>dependent chronic</keyword>
</DOC>